Literature DB >> 21115234

The interaction between N-category and N-ratio as a new tool to improve lymph node metastasis staging in gastric cancer: results of a single cancer center in Brazil.

F J F Coimbra1, W L Costa, A L Montagnini, A L Diniz, H S C Ribeiro, M J B Silva, M F S Begnami.   

Abstract

BACKGROUND: Depth of tumor invasion (T-category) and the number of metastatic lymph nodes (N-category) are the most important prognostic factors in patients with gastric cancer. Recently, the ratio between metastatic and dissected lymph nodes (N-ratio) has been established as one. The aim of this study is to evaluate the impact of N-ratio and its interaction with N-category as a prognostic factor in gastric cancer.
METHODS: This was a retrospective study in which we reviewed clinical and pathological data of 165 patients who had undergone curative surgery at our institution through a 9-year period. The exclusion criteria included metastases, gastric stump tumors and gastrectomy with less than 15 lymph nodes dissected.
RESULTS: The median age of the patients was 63 years and most of them were male. Total gastrectomy was the most common procedure and 92.1% of the patients had a D2-lymphadenectomy. Their 5-year overall survival was 57.7%. T-category, N-category, extended gastrectomy, and N-ratio were prognostic factors in overall and disease-free survival in accordance with univariate analysis. In accordance with TNM staging, N1 patients who have had NR1 had 5-year survival in 75.5% whereas in the NR2 group only 33% of the cases had 5-year survival. In the multivariate analysis, the interaction between N-category and N-ratio was an independent prognostic factor.
CONCLUSION: Our findings confirmed the role of N-ratio as prognostic factor of survival in patients with gastric cancer surgically treated with at least 15 lymph nodes dissected. The relationship between N-category and N-ratio is a better predictor than lymph node metastasis staging.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21115234     DOI: 10.1016/j.ejso.2010.11.002

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  8 in total

1.  Superiority of log odds of positive lymph nodes (LODDS) for prognostic prediction after gastric cancer surgery: a multi-institutional analysis of 7620 patients in China.

Authors:  Pengfei Gu; Jingyu Deng; Zhe Sun; Zhenning Wang; Wei Wang; Han Liang; Huimian Xu; Zhiwei Zhou
Journal:  Surg Today       Date:  2020-08-04       Impact factor: 2.549

2.  Adjuvant radiochemotherapy in locally advanced gastric cancer : Treatment results and analysis of possible prognostic factors.

Authors:  Mercedes Martín Sánchez; Maria Ángeles Pérez Escutia; David Lora Pablos; Sandra Guardado Gonzales; Ana María Cabezas Mendoza; Arantxa Campos Bonel; Héctor Pérez Montero; Rafael D'Ambrosi; José Fermín Pérez-Regadera Gómez
Journal:  Strahlenther Onkol       Date:  2017-07-03       Impact factor: 3.621

3.  The Potential Clinical Implications of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer.

Authors:  Emne A Abdallah; Alexcia C Braun; Bianca C T C P Flores; Laís Senda; Ana Cláudia Urvanegia; Vinicius Calsavara; Victor Hugo Fonseca de Jesus; Maria Fernanda Arruda Almeida; Maria Dirlei Begnami; Felipe J F Coimbra; Wilson Luiz da Costa; Diana Noronha Nunes; Emmanuel Dias-Neto; Ludmilla T Domingos Chinen
Journal:  Oncologist       Date:  2019-03-07

4.  Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients.

Authors:  Wilson L Costa; Felipe J F Coimbra; Héber S C Ribeiro; Alessandro L Diniz; André Luís de Godoy; Mariadirleifs Begnami; Milton J B Silva; Marcelo F Fanelli; Celso A L Mello
Journal:  World J Surg Oncol       Date:  2012-09-19       Impact factor: 2.754

5.  The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial.

Authors:  Youjin Kim; Se Hoon Park; Kyoung-Mee Kim; Min Gew Choi; Jun Ho Lee; Tae Sung Sohn; Jae Moon Bae; Sung Kim; Su Jin Lee; Seung Tae Kim; Jeeyun Lee; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang
Journal:  J Gastric Cancer       Date:  2016-06-24       Impact factor: 3.720

6.  Evaluating the benefit of adjuvant radiotherapy after extensive lymph node dissection for gastric cancer: a single-institute retrospective study.

Authors:  Yu-Nong Wang; Shou-Yi Chang; Jing-Min Hwang; You-Kang Chang; Woei-Yau Kao; Hsiang-Lin Wan; I-Shiang Tzeng; Chao-Chuan Wu
Journal:  Tzu Chi Med J       Date:  2021-02-22

7.  Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center.

Authors:  Wilson L Costa; Felipe J F Coimbra; Ricardo C Fogaroli; Héber S C Ribeiro; Alessandro L Diniz; Maria Dirlei F L Begnami; Celso A L Mello; Marcelo F Fanelli; Milton J B Silva; José Humberto Fregnani; André L Montagnini
Journal:  Radiat Oncol       Date:  2012-10-15       Impact factor: 3.481

8.  Impact on long-term survival of the number of lymph nodes resected in patients with pT1N0 gastric cancer after R0 resection: A multicenter study in China.

Authors:  Jiuda Zhao; Feng Du; Yu Zhang; Jie Kan; Li Dong; Guoshuang Shen; Fangchao Zheng; Hui Chen; Junhui Zhao; Faxiang Ji; Yang Luo; Fei Ma; Ziyi Wang; Binghe Xu
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.